KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C

PHASE3CompletedINTERVENTIONAL
Enrollment

371

Participants

Timeline

Start Date

June 7, 2017

Primary Completion Date

January 25, 2018

Study Completion Date

March 7, 2018

Conditions
Hepatitis C, Chronic
Interventions
DRUG

KW-136 capsule

KW-136 60 mg was provided in a single capsule of 60 mg.

DRUG

Sofosbuvir

Sofosbuvir was provided in a single tablet of 400 mg.

Trial Locations (19)

100039

Chinese PLA 302 Hospital, Beijing

100050

Capital Medical University Affiliated Beijing Youyi Hospital, Beijing

100069

Capital Medical University Affiliated Beijing You'an Hospital, Beijing

100102

Capital Medical University Affiliated Beijing Ditan Hospital, Beijing

110006

Shenyang Municipal Sixth People's Hospital, Shenyang

130021

Jilin University First Hospital, Changchun

133000

Yanbian University Affiliated Hosptial, Yanbian

210003

Nanjing Municipal Second Hospital, Nanjing

250021

Ji'nan Municipal Hospital of Infectious Disease, Ji'nan

400038

Chinese PLA Third Military Medical University First Affiliated Hospital, Chongqing

404000

Chongqing Sanxia Central Hospital, Wanzhou

430030

Huazhong University of Science and Technology Affiliated Tongji Hospital, Wuhan

450015

He'nan Provincial Hospital of Infectious Disease (Zhengzhou Municipal Sixth People's Hospital), Zhengzhou

510060

Guangzhou Municipal Eighth People's Hospital, Guanzhou

510630

Sun Yat-sen University Affiliated Third University, Guangzhou

545006

Liuzhou People's Hospital, Liuzhou

610072

Sichuan Provincial People's Hospital, Chengdu

710038

Chinese PLA Fourth Military Medical University Tangdu Hospital, Xi'an

830000

Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital, Ürümqi

All Listed Sponsors
collaborator

KawinGreen Biotech Co., Ltd.

UNKNOWN

lead

Kawin Technology Share-holding Co., Ltd.

INDUSTRY

NCT03995485 - KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C | Biotech Hunter | Biotech Hunter